Table 9 The impact of metabolic phenotypes on prognosis by univariate analysis
From: Metabolic phenotypes in primary unknown metastatic carcinoma
Clinicopathologic parameters | No. of patients (n = 59*) (%) | Overall survival | ||
|---|---|---|---|---|
No. of cases | Patient death | Median survival (95% CI) (months) | P -value | |
Tumor metabolic type | Â | Â | Â | 0.279 |
 Glycolysis type | 22 | 5 | 52 (37–67) |  |
 Non-glycolysis type | 37 | 13 | 79 (56–102) |  |
Tumor metabolic type | Â | Â | Â | 0.644 |
 Glutaminolysis type | 30 | 10 | 84 (60–108) |  |
 Non-glutaminolysis type | 29 | 8 | 45 (30–59) |  |
Tumor metabolic type | Â | Â | Â | 0.906 |
 Mitochondrial type | 56 | 17 | 84 (66–103) |  |
 Non-mitochondrial type | 3 | 1 | 28 (13–43) |  |
Stroma metabolic type | Â | Â | Â | n/a |
 Glycolysis type | 2 | 0 | n/a |  |
 Non-glycolysis type | 57 | 18 | n/a |  |
Stroma metabolic type | Â | Â | Â | 0.363 |
 Glutaminolysis type | 7 | 1 | 62 (43–80) |  |
 Non-glutaminolysis type | 52 | 17 | 80 (60–100) |  |
Stroma metabolic type | Â | Â | Â | 0.864 |
 Mitochondrial type | 9 | 2 | 28 (18–37) |  |
 Non-mitochondrial type | 50 | 16 | 83 (64–103) |  |